News and Announcements
XCEDA Capital has launched the Xceda Mortgage Income Fund
- Published July 28, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Xceda has recently launched the Xceda Mortgage Income Fund, which invests in short-term bridging mortgages over Australian residential and commercial property. The Fund has a target rate of return of up to 12% p.a., payable in regular monthly or quarterly distributions.
The Fund does not provide construction or development loans – it only provides loans against “As-Is” registered valuations over existing properties, i.e. not against future “As-If Complete” valuations.
The Fund is able to target Rates of Return over 10% p.a. given the short-term bridging nature of this type of mortgage lending, which attracts higher lending rates compared to longer-term residential mortgages.
With over 30 years of experience in funds management across the Xceda Capital Group entities, Xceda has a proven track record of identifying, structuring and managing mortgage loan transactions.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
